Dietary Component [Reference] | Study Type | Characteristics of Participants | Intervention Duration | Intervention Groups | Post-Operative Outcomes | ||
---|---|---|---|---|---|---|---|
n | Surgical Procedure/Clinical Condition | Control | Treatment | ||||
Vitamin B12 [2] | Double-blind, randomized study | 80 | Mandibular third molar extraction in healthy patients, no medication in previous 3 months that might affect inflammatory responses, no systemic diseases, no alcohol, nonsmokers | One tablet 30 min post-operation and for 4 d, once daily | 20 mg piroxicam | 2.5 mg cyanocobalamin with 10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine citrate | Lower pain scores at 6 h and 120 h post-extraction in treatment group. No effect on facial swelling. |
Selenium [3] | Double-blind, randomized study | 20 | Oral tumour surgery | 3 wk, once daily | Placebo | 1000 µg sodium selenite through IV or oral route | Inverse correlation between lymphedema severity and whole blood/plasma selenium concentration and glutathione peroxidase activity. Positive correlation between ROS concentration and extent of lymphedema. Significant reduction of lymphedema in treated group. |
Vitamin B complex [4] | Double-blind, randomized study | 30 | Access flap surgery in patients with generalized moderate to severe chronic periodontitis, ≥2 teeth in same sextant with probing depth ≥ 5 mm and bleeding upon probing | 30 d post-operation, once daily | Placebo | 50 mg each of thiamine, riboflavin, niacinaide, pantothenate and pyridoxine; 50 µg each of biotin and cyanocobalamin; 400 µg of folate |
Better clinical attachment level in vitamin B complex supplemented group. No difference in gingival index, plaque index or bleeding upon probing between groups. |
Vitamin D [5] | Double-blind, randomized study | 40 | Open flap debridement surgery in patients with severe periodontal disease | 3 days pre-surgery, continued daily for 6 wks | Placebo, 1000 mg calcium, 800 IU vitamin D daily | 20 µg teriparatide, 1000 mg Ca, 800 IU vitamin D daily | CAL and PDR in vitamin D sufficient (>20 ng/mL serum 25(OH)D) patients. Vitamin D sufficient patients receiving teriparatide experienced better: CAL at 6 mo, PDR at 3,6, and 9 mo, and RLBG at 6,9, and 12 mo compared to vitamin D insufficient patients also receiving teriparatide. |